<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intravenous (IV) administration of tissue plasminogen activator (tPA) given to patients during <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> according to National Institute of <z:e sem="disease" ids="C1112108" disease_type="Disease or Syndrome" abbrv="">Neurological Disorders</z:e> and <z:hpo ids='HP_0001297'>Stroke</z:hpo> (NINDS) guidelines improves clinical outcome by 11% to 14% </plain></SENT>
<SENT sid="1" pm="."><plain>The success of IV tPA <z:hpo ids='HP_0001297'>stroke</z:hpo> therapy is dependent on several previously reported factors </plain></SENT>
<SENT sid="2" pm="."><plain>The authors suggest that the presence of calcification within an <z:mpath ids='MPATH_110'>embolus</z:mpath> may represent an additional important factor </plain></SENT>
<SENT sid="3" pm="."><plain>This report describes a patient with an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> secondary to a spontaneous calcific cerebral <z:mpath ids='MPATH_110'>embolus</z:mpath> who had a negative outcome despite receiving proper thrombolytic therapy </plain></SENT>
</text></document>